Quantcast

Magenta Therapeutics prices $100 million IPO at $15 midpoint


Shutterstock photo

Magenta Therapeutics, which is developing novel therapies to make stem cell transplants more effective, raised $100 million by offering 6.7 million shares at $15, the midpoint of the $14 to $16 range. Insiders intended to buy $40 million on the IPO (40% of the deal).

Magenta Therapeutics plans to list on the Nasdaq under the symbol MGTA. J.P. Morgan, Goldman Sachs and Cowen acted as lead managers on the deal.

The article Magenta Therapeutics prices $100 million IPO at $15 midpoint originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs



More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs










Research Brokers before you trade

Want to trade FX?